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Abstract
Background: Due to the increasing rates of oropharyngeal cancer, oral HPV infection is a significant concern.
Methods for detecting oral HPVs is not standardized as there are different techniques available. We propose that
use of oral rinse samples to detect for HPVs is a suitable technique within a clinic setting. Thus, our main objective
is to study HPV detection in oral rinse samples.
Methods: In our study, we used oral rinse sample collection coupled with real-time PCR to detect for HPVs types
16 and 18, and preferentially amplified FAP PCR samples to detect for a broad range of HPVs, in oropharyngeal
squamous cell carcinoma (OPSCC), non-OPSCC, and healthy patients.
Results: Thirty three percent of 100 cancer patients were positive for any type of HPV; of those 23 were positive for
HPV16. Only 1 of 110 healthy controls was positive (this subject was positive for HPV18).
Conclusion: Our results indicate that HPV detection in oral rinse samples may be useful as a screening tool to
detect HPV-associated oral cancers.
Background
Tissues infected by human papillomavirus (HPV) have
the ability to evolve into an HPV-associated cancer. This
is likely due to a field effect where HPV can modify
regular cell functions resulting in malignancy. Though
we know how to test for HPV-related cancers, there is
currently no standard for detecting HPV infection [1],
and screening for HPV could identify individuals at risk
for head and neck squamous cell carcinoma (HNSCC).
Speaking of which, HNSCC cases associated with HPV
have been a challenge to screen for, especially oral cavity
squamous cell carcinoma (OSCC) and oropharyngeal
squamous cell carcinoma (OPSCC) cases, which are
subsets of HNSCC. The oropharyngeal area includes the
base of the tongue, soft palate, tonsils, and tonsillar
region, with the oral cavity encompassing the rest of the
interior tissues of the mouth. The most common
methods for HPV detection within the mouth and oro-
pharynx begin with collection of cells with a cotton
swab, cytobrush, or a mouth rinse [2], followed by the
use of PCR-based assays or DNA in situ hybridization
[3]. However, there are challenges present for certain
techniques. For example, the use of a swab/brush limits
the amount of mucosa that is sampled, and obtaining a
sample from a non-visible lesion within the tonsillar
crypt may not be feasible [4]. The base of the tongue is
not entirely accessible either as there is both flat mucosa
and tonsillar tissue, thus increasing the risk for false
negatives [5]. We chose to use a mouth rinse technique
for sample collection as it is non-invasive, quick, and
simple for the patient.
Analyzing p16 expression has been used as a bio-
marker for HPV-associated OSCC/OPSCC, but studies
have reported that p16 overexpression is not always
present in cases involving oncogenic HPVs [6–9]. A re-
cent study concluded that p16 should not be used as a
surrogate marker for HPV infection in oral cancers due
to poor concordance between the two [10]. Previous to
this, Pannone et al. also stated that p16 immunohisto-
chemistry (IHC) alone does not prove to be a reliable
method in HPV detection for OSCC/OPSCC cases [11].
Within our study, we obtained information for p16
testing to see whether or not our HPV data was in
concordance.
OPSCC incidence in developed countries has increased
significantly and HPV infection is proposed to be the main
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factor [12]. Risk factors for oral HPV infection include
certain sexual practices [13–16]; number of lifetime
partners and number of recent sex partners, older age,
being male, and current cigarette smoking [17, 18]. The
most prevalent type of HPV associated with oral infec-
tion is type 16 [17, 19], which has been demonstrated to
be oncogenic in HNSCCs [20]. A worldwide systematic
review of HNSCC biopsies demonstrated HPV16 in
31 % of OPSCC cases; 16 % of OSCC cases; and 17 % of
laryngeal SCC cases [21]. HPV type 18 also appears to
play a significant role in carcinogenesis, especially in the
oropharynx [22, 23].
With the rise of OPSCCs it is imperative to have a
gold-standard technique in place for oral HPV detection.
Collecting samples from the oral cavity and oropharynx
for the detection of oral HPVs should be quick, non-
invasive, inexpensive, and sufficient in HPV DNA col-
lection. In our study, we investigated oral rinse samples
coupled with real-time PCR Taqman assays to detect
for HPV types 16 and 18, which is sensitive and spe-
cific. To detect for a broad range of HPVs, we prefer-
entially amplified the oral rinse samples from cancer
cases, and used fluorescent arbitrarily primed (FAP)
PCR, a general PCR method using degenerate HPV
primers.
Study population
Between 2011 and 2013, we recruited 76 OPSCC
and 24 non-OPSCC patients from the Seattle Cancer
Care Alliance (Seattle, WA), and 110 healthy sub-
jects from University of Washington Dental Clinic
(Seattle, WA). Non-OPSCC cases included patients
with OSCC, laryngeal, sinus, and supraglottis can-
cers. We screened the schedules of five oncologists
in order to identify eligible cancer patients, and dis-
cussed our study at their appointment. One patient
declined due to mouth sores and sensitivity. 21/100
cancer patients had already begun treatment and of
these 21 patients: 18 patients had treatment less
than 21 days before sampling, two had over 30 days
of treatment, and one patient had treatment for
7 months. Healthy subjects were randomly selected
within the student dental clinic, one patient declined
to take part in the study. Inclusion requirements for
the healthy population included being: cancer-free,
not pregnant, HIV-free, and over the age of 16. Each
patient signed written consent forms to participate
in the study (IRB #7490 approved April 9, 2014),
and answered a simple health questionnaire. Gender,
age, race, smoking, alcohol, and marijuana history
were recorded for all subjects. Charts for a subset of
our patients were reviewed for p16 immunohisto-
chemistry (IHC) and HPV testing.
Methods
Collection & DNA purification methods
For sample collection, all patients rinsed and gargled for
30 s with Original Mint Scope® mouthwash (Procter &
Gamble). Four normal healthy individuals requested to
use Crest® Alcohol-free mouthwash due to a history of
alcoholism. Oral rinse samples were centrifuged for
15 min. at 4 °C to form a pellet, the supernatant was dis-
carded, and the pellet was placed in -80 °C until further
processing. The Puregene® DNA Purification Kit was
used to isolate genomic DNA from the buccal cell pellet
within the mouthwash samples (Qiagen item #158467,
manufacturer’s protocol was followed).
All human subjects IRB protocols and regulations were
followed under the Fred Hutchinson Cancer Research
Center guidelines (IRB #7490 approved April 9, 2014).
HPV & analytic methods
Taqman real-time PCR assays were used for detection
on the ABI Prism 7900 Sequence Detection System with
40 cycles in a reaction (denaturation at 95 °C, annealing
and extension at 60 °C). Absolute quantification was
used to determine HPV16 and 18 viral load, and total
human genomic DNA in the sample was determined on
Alu sequences. Serial dilutions of human genomic DNA
and full length HPV16 and 18 plasmids, of known con-








HPV18 E7 Probe: AACGTCACACAATGTT
In order to increase the efficiency of HPV detection, we
used the multiply-primed rolling-circular amplification
technique (MP-RCA) to preferentially amplify unknown,
circular HPV DNA. MP-RCA has been demonstrated to
amplify circular DNA templates up to 107-fold [24]. The
TempliPhi 100 Amplification Kit (Amersham Biosciences)
protocol was followed.
The FAP PCR published protocol was followed to detect
for a broad range of HPV types where primers were devel-
oped from conserved L1 regions [25]. We only performed
this technique on the cancer case samples (Fig. 1).
We categorized smoking history as follows: non-
smoker (0 packs); light smoker (<1pack/week); moderate
smoker (≥1pack/week ≤1 pack/day); heavy smoker
(≥1pack/day). For those who smoked cigars or chewed
tobacco we calculated to the equivalent of packages of
cigarettes smoked. Alcohol history was categorized as
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follows: none (never drinks); rarely/occasionally (1 drink
every 1–2 months); light (1–6 drinks/week for females,
1–13 drinks/week for males); moderate (7 drinks/week
for females, 14 drinks/week for males); heavy (>7drinks/
week for females, >14 drinks/week for males).
All data analysis was done using Stata MP 13.1
(StataCorp LP, Texas, USA).
Results
Oral cancer subjects with OPSCC and non-OPSCC
were more likely to be male than control subjects
without cancer, as at least 83 % of subjects in each
cancer type were male, compared to only 46 % of con-
trols (Table 1; p <0.001). Cancer cases were also older
than controls, as >80 % of cases, regardless of cancer
type, were 50 years of age or older compared to only
63 % of controls (p <0.001). Subjects with OPSCC and
non-OPSCC were similar to subjects without cancer
with respect to race (p = 0.30) and ethnicity (p = 0.62)
and were predominately non-Hispanic Caucasians.
Those who had cancer (39 % OPSCC, 54 % non-
OPSCC; p <0.001) were more likely to be heavy
smokers compared to those with no cancer (32 %).
Heavy alcohol history was prevalent in 33 % of OPSCC
and in 33 % of OSCC patients (p = 0.015) compared to
only 12 % of non-cancer subjects. Marijuana use was
mainly observed in cancer cases (11 % OPSCC, 4 %
OSCC; p = 0.010) and rarely in controls (0.91 %). Cases
of both cancer types (33 % OPSCC, 33 % non-OPSCC;
p <0.001) were more likely to have detectable HPV
than healthy controls (0.9 %), and specifically type 16
(25 % OPSCC, 17 % non-OPSCC; p <0.001) detected
in their oral rinse samples compared to controls.
HPV18 detection did not vary by study group and was
detected in a single sample from a control subject (p
= 0.63), and none in the cancer cases. Our method for
HPV detection had a sensitivity of 33 % and specificity
of 99 % (p <0.001).
Twenty-two HPV positive samples were tested for p16
prior to sampling, and only one tested negative for p16.
However, 26 samples that were negative for HPV were
positive for p16 (Table 2). It should be noted that three
of the 26 patients (p = 0.085) underwent treatment (ie.
chemotherapy, radiation therapy, excision) prior to sam-
pling, which could affect the presence of prior HPV in-
fection. HPV was marginally associated with p16
detection (p = 0.076); of patients who were HPV positive,
96 % had a positive p16 test; only one sample that was
positive for HPV tested negative for p16. Amongst HPV
negative patients, 79 % were p16 positive. Only two case
patients had HPV screening completed before sampling
and both were negative for HPV in our tests and the
screening.
Discussion
Patient sample collection can be a difficult and time
consuming task especially when the researcher is inter-
rupting an appointment. Also, many individuals have
sensitive gag reflexes, thus if a brush or swab technique
is used to scrape the back of the throat, obtaining a sam-
ple may be quite difficult without the aid of a topical
anesthetic. This is why it is imperative to have a sam-
pling technique in place that is non-invasive and quick,
yet sufficient for detection of HPV. Our study has dem-
onstrated that oral rinse sample collection is an unob-
trusive method to use for detection of oral HPVs. This is
in concordance with a study comparing oral rinse and
cytology brush sampling, which concluded that oral
rinses were the best choice for sampling from the oral
cavity in order to detect for HPV [26].
We used Scope® because it was observed to have excel-
lent preservation of high-molecular-weight DNA quality,
and it is more palatable than most other rinse media
[27]. Four control patients requested to rinse with Crest
Pro-Health® non-alcoholic mouthwash. We did not see
differences in DNA quantity (data not shown), however
more research is required to see if there is a difference
with quantity as well as quality.
Quantifying viral load may be crucial in determining
whether HPV-positive OPSCC/OSCCs are unquestion-
ably the result of HPV infection [28]. The gold-standard
for HPV viral load assessment is real-time PCR [29, 30].
One study demonstrated OPSCC to have a viral load of
~80,000 times higher than OSCC and other HNSCCs
Fig. 1 FAP PCR results on an electrophoresis gel. An expected band
of ~480 bp indicates an HPV positive sample
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[29]. Our results showed no significant differences
between the two cancer groups (Fig. 2). As well, differ-
ences in results could be due to the authors using fresh-
frozen biopsies where only a small portion of the oral
cavity or oropharynx is sampled. Oral rinse samples may
allow for a more effective collection of oral cells for
HPV detection. Variation in findings warrants further
able 1 Demographics amongst all subjects in non-cancer and cancer cases
No cancer OPSCC Non-OPSCC p-value
n = 110 n = 76 n = 24
Gender
Male 51 (46.36 %) 63 (82.89 %) 20 (83.33 %) <0.001
Female 59 (53.64 %) 13 (17.11 %) 4 (16.67 %)
Grouped age
20–39 27 (24.55 %) 1 (1.32 %) 1 (4.17 %)
40–49 13 (11.82 %) 10 (13.16 %) 2 (8.33 %)
50–59 21 (19.09 %) 29 (38.16 %) 11 (45.83 %) <0.001
60–69 29 (26.36 %) 30 (39.47 %) 8 (33.33 %)
70+ 20 (18.18 %) 6 (7.89 %) 2 (8.3 %)
Race
Asian 5 (5.55 %) 2 (2.63 %) 1 (4.17)
Black 6 (5.45 %) 1 (1.32 %) 0
White 92 (83.64 %) 65 (85.53 %) 21 (87.50 %) 0.30
Other 7 (6.36 %) 4 (5.26 %) 1 (4.17 %)
Unknown 0 4 (5.26 %) 1 (4.17 %)
Ethnicity (Hispanic/Latino)
Yes 4 (3.64 %) 2 (2.63 %) 0 0.62
No 106 (96.36 %) 74 (97.37 %) 24 (100 %)
Smoking history
Non-smoker 51 (46.36 %) 21 (27.63 %) 5 (20.83 %)
Light smoker 1 (0.91 %) 14 (18.42 %) 2 (8.33 %) <0.001
Moderate smoker 23 (20.91 %) 11 (14.47 %) 4 (16.67 %)
Heavy smoker 35 (31.82 %) 30 (39.47 %) 13 (54.17 %)
Alcohol history
None 24 (21.82 %) 7 (9.21 %) 3 (12.50 %)
Rarely/occasionally 16 (14.55 %) 14 (18.42 %) 4 (16.67 %)
Light 54 (49.09 %) 27 (35.53 %) 9 (37.50 %) 0.015
Moderate 3 (2.73 %) 3 (3.95 %) 0
Heavy 13 (11.82 %) 25 (32.89 %) 8 (33.33 %)
Any Marijuana use
Yes 1 (0.91 %) 8 (10.53 %) 1 (4.17 %) 0.010
No 109 (99.09 %) 68 (89.47 %) 23 (95.83 %)
Any HPV 1 (0.91 %) 25 (32.89 %) 8 (33.33 %) <0.001
HPV 16 positive 0 19 (25.00 %) 4 (16.67 %) <0.001
HPV 18 positive 1 (0.91 %) 0 0 0.63
aData for “No Cancer” is associated with published data from Prevalence of HPV types 16 and 18 within a dental student clinic setting (J Dang et al.)
Table 2 p16 and any HPV
Any HPV p16 test p-value
Positive Negative 0.076
n = 48 n = 8
Yes 22 (95.65 %) 1 (4.35 %)
No 26 (78.79 %) 7 (21.21 %)
Dang et al. BMC Oral Health  (2015) 15:126 Page 4 of 6
investigation of viral load in association with subsets of
HNSCC.
The one patient with OPSCC, who had undergone
treatment for 7 months prior to sampling, was posi-
tive for HPV, specifically type 16. This case is unique
as undergoing several months of treatment should
eradicate the virus unless if the infection was recent.
It should be noted that the patient had a heavy
smoking and drinking history. More research on preva-
lence of HPV infection after radiation/chemotherapy is
warranted.
One major limitation was not having DNA from
tumor tissue to compare HPV detection. The tissue
samples were not available to us, but would have acted
as a gold standard within our study. Other limitations to
our study include: our results demonstrating a low sensi-
tivity for HPV detection in cancer patients, but with a
very high specificity; we could not control how well a
patient would gargle and swish the mouthwash, which
will have an effect on the quantity and quality of DNA
collected; Scope® has a strong mint taste, which may not
be suitable for those with sensitive mouths; small sample
size; not detecting for HPV RNA to show active infec-
tion; and FAP PCR is sensitive enough to detect for a
broad range of HPVs, but some HPVs may not be de-
tected due to the generality of the designed primers [25].
p16 testing is usually only performed in cases where
they do not fit the traditional risk factors (ie. significant
tobacco and alcohol use history), and HPV testing is
rarely done. This is something that needs to be changed
during diagnosis due to the increase in HPV-associated
OPSCCs.
Conclusions
From our results we demonstrated that preferentially
amplified oral rinse samples with HPV detection from
real-time PCR Taqman assays and FAP PCR, is a usable
method overall, which could be used within a clinic
setting. More specific studies will need to be done to
determine whether mouth rinses do actually reflect, in
cases, the type of HPV associated with the cancerous
lesion.
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